CHM 0.00% 1.4¢ chimeric therapeutics limited

Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-5

  1. 329 Posts.
    lightbulb Created with Sketch. 16
    The first patient in the Phase 1B clinical trial was dosed at the Sarah Cannon Transplant &
    Cellular Therapy Program at St. David’s South Austin Medical Center in Austin, Texas. The
    patient received CHM 1101 therapy as second line therapy.

    So they're moving to earlier initiations?
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.